Dyax Corp

Most Recent

  • uploads///Graph Part
    Company & Industry Overviews

    XBI Moving Averages Are on the Rise

    For the week ended September 11, 2015, the SPDR S&P Biotechnology ETF (XBI) saw a big jump in the number of stocks trading above the 20-day moving average.

    By Peter Neil
  • uploads///Graph Part  OCt
    Company & Industry Overviews

    IMMU and ACRX Outperform in the Biotech Downdraft

    Immunomedics (IMMU) rose by 13% on October 6, 2015. The stock rose on buying support with good trade volumes. The stock closed at $2.08.

    By Peter Neil
  • uploads///chart
    Company & Industry Overviews

    How Has EBSAX Performed in the Market?

    Managed futures The Equinox Campbell Strategy Fund Class A (EBSAX) is an alternative mutual fund that seeks to achieve its investment objectives by using the “managed futures” strategy. The Natixis ASG Managed Futures Strategy Fund Class A (AMFAX) and the Direxion Indexed Commodity Strategy Fund Class A (DXCTX) use similar alternative managed futures strategies. 7 […]

    By Ivan Kading
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    On a Bullish Day, IBB Outperformed XLV

    The iShares Nasdaq Biotechnology ETF (IBB) rose 4.4%, the Health Care Select Sector SPDR ETF (XLV) rose 2.2%, and the SPDR S&P 500 ETF (SPY) moved up by 1.5% on October 15.

    By Peter Neil
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    The SPDR S&P Biotech ETF Lingers in the Red as of December 3

    The SPDR S&P Biotech ETF (XBI) went down by 3.9% on December 3, which represents the third consecutive day of declines for the ETF. XBI closed at $68.91.

    By Peter Neil
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Shire-Dyax Merger Drove Biotech Stocks

    Shire (SHPG) announced that it will acquire Dyax (DYAX) for $37.30 per Dyax share in a deal valued at ~$5.9 billion.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Pacira’s Strong 3Q15 Results Helped the Pharma Subgroup

    Pacira Pharmaceuticals (PCRX) rose 19.5% and closed at $49.12. Pacira had a weight of 0.25% in IBB’s portfolio. It was one of the top performers on October 27.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    XBI’s Top Ten Small-Cap Stocks Perform on Par with Large-Caps

    In the small-cap space, the top ten stocks of XBI had an average return of -12.18% for the week ended September 25, 2015. This is similar to XBI’s top ten large-cap stocks that returned -12.15%.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    ENDP Traded above 100-Day Moving Average in Week to September 18

    ENDO International (ENDP) rose 9.52%. The stock went up on high trading volumes during September 16-18.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Dyax Traded above Its 100-Day Moving Average

    Dyax (DYAX) gained 9.41% last week. The stock went up after Dyax presented at the Morgan Stanley global healthcare conference, which took place September 16-18 in New York.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Moving Average Analysis of the Pharmaceutical Subgroup

    For the week ending July 31, the stocks that moved into the 100-day moving average zone include Akorn, Clovis Oncology, Endo International, and Grifols.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Key for Investors: How Are Biotech Stocks Trending?

    Dyax (DYAX) had stocks that fell out of the 100-day moving averages. Dyax reported revenue of $26.4 million and a net loss of $8.4 million.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.